Drug Profile
Research programme: antimicrobial therapies - NovaBiotics
Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Innovate UK; NovaBiotics
- Developer NovaBiotics
- Class Amino acids peptides and proteins; Antibacterials; Antifungals; Peptides; Peptidomimetics; Small molecules
- Mechanism of Action Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acne; Clostridium difficile infections; Methicillin-resistant Staphylococcus aureus infections; Pseudomonal infections
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in United Kingdom (Inhalation, Aerosol)
- 28 Mar 2022 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in United Kingdom (Topical)
- 28 Jul 2019 No recent reports of development identified for preclinical development in Clostridium-difficile-infections in United Kingdom (Inhalation, Aerosol)